Brinzolamide/brimonidine

Combination of
Brinzolamide	Carbonic anhydrase inhibitor
Brimonidine	Alpha-adrenergic agonist
Clinical data
Trade names	Simbrinza
AHFS/Drugs.com	Professional Drug Facts
Licence data	EMA:Link, US Daily Med:link
Pregnancy category	AU: B3
Legal status	UK: POM (Prescription only) US: ℞-only EU: Rx-only ℞ (Prescription only)
Routes of administration	Eye drop
Identifiers
ATC code	S01EC54 (WHO)
PubChem	CID: 9961469
KEGG	D10854

Brinzolamide/brimonidine, sold under the brand name Simbrinza, is a fixed-dose combination medication used to reduce intra-ocular pressure (pressure inside the eye) in adults with ocular hypertension (high intra-ocular pressure) or in those with an eye condition known as open-angle glaucoma. It contains brinzolamide and brimonidine tartrate. It is used as an eye drop.

The most common side effects include ocular hyperaemia (red eye), allergic reactions in the eye, and dysgeusia (taste disturbances).

Open-angle glaucoma (a condition where the aqueous humour, the watery fluid inside the eyeball, cannot drain away properly) and other causes of high pressure in the eye increase the risk of damage to the retina and the optic nerve (the nerve that sends signals from the eye to the brain). This can result in serious vision loss and even blindness.

The active substances, brinzolamide and brimonidine tartrate, help to reduce intra-ocular pressure by reducing the production of aqueous humour. Brinzolamide works by blocking an enzyme called carbonic anhydrase, which produces bicarbonate needed for the production of the aqueous humour, while brimonidine tartrate blocks another enzyme known as adenylate cyclase, which is also involved in the production of the aqueous humour. Brimonidine also increases the drainage of aqueous humour from the front of the eye.

Brinzolamide/brimonidine was approved for medical use in the United States in April 2013, and in the European Union in July 2014.

Medical uses

Brinzolamide/brimonidine is indicated to decrease of elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

History

Brinzolamide/brimonidine was approved for medical use in the United States in April 2013, and in the European Union in July 2014.